Cargando…

A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients

Background: Pyroptosis is a form of programmed cell death accompanied by specific inflammatory and immune responses, and it is closely related to the occurrence and progression of various cancers. However, the roles of pyroptosis-related genes (PRGs) in the prognosis, treatment response, and tumor m...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Xi, Li, Jianpeng, Wan, Shun, Wu, Mingzhe, Li, Zonglin, Tian, Junqiang, Mi, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648539/
https://www.ncbi.nlm.nih.gov/pubmed/36386841
http://dx.doi.org/10.3389/fgene.2022.1006151
_version_ 1784827603546275840
author Xiao, Xi
Li, Jianpeng
Wan, Shun
Wu, Mingzhe
Li, Zonglin
Tian, Junqiang
Mi, Jun
author_facet Xiao, Xi
Li, Jianpeng
Wan, Shun
Wu, Mingzhe
Li, Zonglin
Tian, Junqiang
Mi, Jun
author_sort Xiao, Xi
collection PubMed
description Background: Pyroptosis is a form of programmed cell death accompanied by specific inflammatory and immune responses, and it is closely related to the occurrence and progression of various cancers. However, the roles of pyroptosis-related genes (PRGs) in the prognosis, treatment response, and tumor microenvironment (TME) of prostate cancer (PCa) remain to be investigated. Methods: The mRNA expression data and clinical information of PCa patients were obtained from the Cancer Genome Atlas database (TCGA) and the cBioPortal for Cancer Genomics website, and the 52 PRGs were obtained from the published papers. The univariate, multivariate, and LASSO Cox regression algorithms were used to obtain prognostic hub PRGs. Meanwhile, qRT-PCR was used to validate the expression of hub genes between PCa lines and normal prostate epithelial cell lines. We then constructed and validated a risk model associated with the patient’s disease-free survival (DFS). Finally, the relationships between risk score and clinicopathological characteristics, tumor immune microenvironment, and drug treatment response of PCa were systematically analyzed. Results: A prognostic risk model was constructed with 6 hub PRGs (CHMP4C, GSDMB, NOD2, PLCG1, CYCS, GPX4), and patients were divided into high and low-risk groups by median risk score. The risk score was confirmed to be an independent prognostic factor for PCa in both the training and external validation sets. Patients in the high-risk group had a worse prognosis than those in the low-risk group, and they had more increased somatic mutations, higher immune cell infiltration and higher expression of immune checkpoint-related genes. Moreover, they were more sensitive to cell cycle-related chemotherapeutic drugs and might be more responsive to immunotherapy. Conclusion: In our study, pyroptosis played a significant role in the management of the prognosis and tumor microenvironment of PCa. Meanwhile, the established model might help to develop more effective individual treatment strategies.
format Online
Article
Text
id pubmed-9648539
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96485392022-11-15 A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients Xiao, Xi Li, Jianpeng Wan, Shun Wu, Mingzhe Li, Zonglin Tian, Junqiang Mi, Jun Front Genet Genetics Background: Pyroptosis is a form of programmed cell death accompanied by specific inflammatory and immune responses, and it is closely related to the occurrence and progression of various cancers. However, the roles of pyroptosis-related genes (PRGs) in the prognosis, treatment response, and tumor microenvironment (TME) of prostate cancer (PCa) remain to be investigated. Methods: The mRNA expression data and clinical information of PCa patients were obtained from the Cancer Genome Atlas database (TCGA) and the cBioPortal for Cancer Genomics website, and the 52 PRGs were obtained from the published papers. The univariate, multivariate, and LASSO Cox regression algorithms were used to obtain prognostic hub PRGs. Meanwhile, qRT-PCR was used to validate the expression of hub genes between PCa lines and normal prostate epithelial cell lines. We then constructed and validated a risk model associated with the patient’s disease-free survival (DFS). Finally, the relationships between risk score and clinicopathological characteristics, tumor immune microenvironment, and drug treatment response of PCa were systematically analyzed. Results: A prognostic risk model was constructed with 6 hub PRGs (CHMP4C, GSDMB, NOD2, PLCG1, CYCS, GPX4), and patients were divided into high and low-risk groups by median risk score. The risk score was confirmed to be an independent prognostic factor for PCa in both the training and external validation sets. Patients in the high-risk group had a worse prognosis than those in the low-risk group, and they had more increased somatic mutations, higher immune cell infiltration and higher expression of immune checkpoint-related genes. Moreover, they were more sensitive to cell cycle-related chemotherapeutic drugs and might be more responsive to immunotherapy. Conclusion: In our study, pyroptosis played a significant role in the management of the prognosis and tumor microenvironment of PCa. Meanwhile, the established model might help to develop more effective individual treatment strategies. Frontiers Media S.A. 2022-10-27 /pmc/articles/PMC9648539/ /pubmed/36386841 http://dx.doi.org/10.3389/fgene.2022.1006151 Text en Copyright © 2022 Xiao, Li, Wan, Wu, Li, Tian and Mi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Xiao, Xi
Li, Jianpeng
Wan, Shun
Wu, Mingzhe
Li, Zonglin
Tian, Junqiang
Mi, Jun
A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients
title A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients
title_full A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients
title_fullStr A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients
title_full_unstemmed A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients
title_short A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients
title_sort novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648539/
https://www.ncbi.nlm.nih.gov/pubmed/36386841
http://dx.doi.org/10.3389/fgene.2022.1006151
work_keys_str_mv AT xiaoxi anovelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients
AT lijianpeng anovelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients
AT wanshun anovelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients
AT wumingzhe anovelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients
AT lizonglin anovelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients
AT tianjunqiang anovelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients
AT mijun anovelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients
AT xiaoxi novelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients
AT lijianpeng novelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients
AT wanshun novelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients
AT wumingzhe novelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients
AT lizonglin novelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients
AT tianjunqiang novelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients
AT mijun novelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients